Patents Examined by Stephen L. Rawlings
  • Patent number: 10815302
    Abstract: This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: October 27, 2020
    Assignees: Shanghai Junshi Biosciences Co., Ltd., Junmeng Biosciences Co., Ltd.
    Inventors: Bo Chen, Hai Wu, Hui Feng
  • Patent number: 10808038
    Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 20, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Birgit Bossenmaier, Richard Buick, Stefan Dengl, Michael Gerg, Carmen Peess, Wolfgang Schaefer, Michael Schraeml, Claudio Sustmann
  • Patent number: 10808030
    Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: October 20, 2020
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Paul Vink
  • Patent number: 10793593
    Abstract: The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc.) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: October 6, 2020
    Assignee: EMD Millipore Corporation
    Inventor: Wilson Moya
  • Patent number: 10792350
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: October 6, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Patent number: 10793636
    Abstract: Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same. The antibodies provided include amino acid substitution embodiments affecting the antibody glycosylation state. The antibodies provided herein are, inter alia, useful for the treatment of cancer and effective for inhibition of CD73 activity.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: October 6, 2020
    Assignee: CORVUS PHARMACEUTICALS, INC.
    Inventors: Emily Piccione Griffin, Richard A. Miller, Ian McCaffery
  • Patent number: 10780125
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 22, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10781264
    Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: September 22, 2020
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
  • Patent number: 10774152
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Patent number: 10766943
    Abstract: The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: September 8, 2020
    Assignee: GEMoaB Monoclonals GmbH
    Inventors: Michael Bachmann, Armin Ehninger
  • Patent number: 10766967
    Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 8, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
  • Patent number: 10729755
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: August 4, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
  • Patent number: 10730952
    Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: August 4, 2020
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson
  • Patent number: 10722536
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: July 28, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10703806
    Abstract: The present specification discloses SNAP-25 compositions, methods of making ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, ?-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P1 residue from the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product, methods of detecting BoNT/A activity, and methods of detecting neutralizing ?-BoNT/A antibodies.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: July 7, 2020
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Joanne Wang, Patton Garay, Lina S. Wong, D. Dianne Hodges, Kei Rogers Aoki
  • Patent number: 10697966
    Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: June 30, 2020
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Ruediger Ridder, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
  • Patent number: 10696738
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: June 30, 2020
    Assignee: Glaxon Group Limited
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • Patent number: 10689456
    Abstract: The invention provides a chimeric antigen receptor (CAR) having antigenic specificity for CD70, the CAR comprising: an antigen binding-transmembrane domain comprising a CD27 amino acid sequence lacking all or a portion of the CD27 intracellular T cell signaling domain; a 4-1BB intracellular T cell signaling domain; a CD3? intracellular T cell signaling domain; and optionally, a CD28 intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: June 23, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Qiong J. Wang, Zhiya Yu, James C. Yang
  • Patent number: 10688131
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: June 23, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Anita Wiebe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10676532
    Abstract: The present invention provides methods and compositions for determining sepsis in an individual. Specifically, the present invention provides for antibodies of fragments thereof that specifically bind to presepsin. The antibodies of the present invention may be monoclonal antibodies, and they may specifically bind to a particular epitope of presepsin. The present invention further provides methods of using such antibodies to determine whether an individual has sepsis, and kits comprising the disclosed antibodies.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 9, 2020
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventor: Kamon Shirakawa